1.1Periostin transcript degradation
A lipid carrier delivers a short interfering RNA duplex to dermal fibroblasts. The guide strand directs cleavage of complementary periostin messenger RNA, reducing secretion of newly synthesized periostin.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A lipid carrier delivers a short interfering RNA duplex to dermal fibroblasts. The guide strand directs cleavage of complementary periostin messenger RNA, reducing secretion of newly synthesized periostin.
A cream releases an amide local anesthetic into superficial skin. The anesthetic blocks voltage-gated sodium channels in cutaneous sensory fibers and reduces propagation of itch-related action potentials.
Micronized particles of the compound are dispersed in water with a nonionic wetting agent and a cellulose thickener. The suspension delivers a measured mass of the compound, and dissolved molecules become available to interact with the receptor.
An anhydrous solid is blended with microcrystalline cellulose and filled into a hard capsule. The capsule opens in gastrointestinal fluid, which wets the powder and dissolves the active compound.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An air–liquid interface culture holds canine skin explants with the epidermis facing air and the dermis contacting culture medium. The medium contains recombinant canine periostin and one of the listed small-molecule receptor antagonists, with a vehicle-treated explant from the same specimen as a control. Histology and epidermal cytokine measurements compare tissue responses across conditions.
A periostin-neutralizing monoclonal antibody replaces the small-molecule receptor antagonist as the active ingredient. The antibody binds extracellular periostin and reduces its interaction with cell-surface integrins. A cell adhesion assay uses periostin-coated wells to compare the antibody with a matched isotype control.
A 96-well plate holds periostin-coated test wells, uncoated controls and vehicle controls. Integrin-expressing cells receive an eight-point, threefold dilution series of a listed antagonist starting at 10 micromolar, with three replicate wells per concentration. After 45 minutes, a wash removes unattached cells and fluorescence imaging counts the remaining cells. A parallel viability assay measures cell survival at the same concentrations.
A vertical diffusion cell holds excised skin between a donor chamber and a stirred receiver chamber, with the epidermis facing the donor. The donor chamber holds a hydrogel containing a listed antagonist, and the receiver contains a buffered fluid selected to keep the compound in solution. Liquid chromatography measures antagonist in serial receiver samples and in an extract of the skin at the end of the run.
A permeable insert supports an epidermal culture above a well containing sensory neurons, with shared medium connecting the two compartments. Recombinant periostin and a listed antagonist enter the shared medium, and separate wells receive periostin with vehicle or vehicle alone. Time-lapse calcium imaging records neuronal response frequency and amplitude following treatment.
A liquid handler dispenses a listed antagonist and vehicle into periostin-coated wells and adds fluorescently labeled integrin-expressing cells. After a timed incubation and a standardized wash, an automated microscope acquires fields at fixed positions in each well. Image analysis counts labeled cells, and software normalizes counts to the vehicle wells and fits a concentration–response curve.
A monoclonal antibody binds a surface on periostin involved in integrin recognition. Antibody-bound periostin has fewer accessible binding sites for engaging integrins on nearby cells.
A small molecule binds the ligand-recognition site of a periostin-binding integrin on the cell surface. Occupancy of that site reduces periostin binding and downstream integrin signaling.
The dichlorophenyl compound is formulated as a chloride salt with its guanidine group protonated. Dissolution releases the active molecular species and chloride into the aqueous phase.
An ethyl ester masks the carboxyl group of the dichlorophenyl compound. Esterase-mediated hydrolysis releases the parent carboxylic acid and ethanol.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
An antipruritic agent comprising a nociceptine antagonist as an active ingredient.A · US 2008/0103162 A1 · claim 1
The present invention concerns methods of assessing the effect, efficacy, safety, and/or dosing of therapeutic agents (or drug), such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders.B · US 2017/0102393 A1 · ¶ 3
An empty cell means only that no passage was reproduced there.
As described above, there are no satisfactory medicaments for diseases associated with itching and it is required to develop a medicament which effectively suppresses itching regardless of causative diseases from a clinical point of view.A · US 2008/0103162 A1 · ¶ 4
As a result, they have found that a nociceptine antagonist has an antipruritic effect.A · US 2008/0103162 A1 · ¶ 7
Additionally, the present invention provides methods of using such biomarkers to design a drug treatment and/or dosing regimen, or for prognosis.B · US 2017/0102393 A1 · ¶ 3
Therefore, it is desirable to develop a biomarker that can accurately predict and/or track the responsiveness of a patient to treatment with a therapeutic agent.B · US 2017/0102393 A1 · ¶ 8
patent.fyi, US 2026/0355192 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355192/, SHA-256 18043326e6ec9de5ce10fe0266e39429ca154069e514901a043a6c2225b64f63